G
Gemma L. Kelly
Researcher at Walter and Eliza Hall Institute of Medical Research
Publications - 70
Citations - 4855
Gemma L. Kelly is an academic researcher from Walter and Eliza Hall Institute of Medical Research. The author has contributed to research in topics: Apoptosis & Epstein–Barr virus. The author has an hindex of 26, co-authored 55 publications receiving 3582 citations. Previous affiliations of Gemma L. Kelly include University of Birmingham & University of Melbourne.
Papers
More filters
Journal ArticleDOI
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy,Szlávik Zoltán,James A. H. Murray,James Edward Paul Davidson,Ana Leticia Maragno,Gaëtane Le Toumelin-Braizat,Maïa Chanrion,Gemma L. Kelly,Gemma L. Kelly,Jia-Nan Gong,Jia-Nan Gong,Donia M Moujalled,Alain Bruno,Csékei Márton,Attila Paczal,Zoltán B. Szabó,Szabolcs Sipos,Gabor Radics,Proszenyák Ágnes,Balázs Bálint,Levente Ondi,Gábor Blasko,Alan P. Robertson,Allan E. Surgenor,Pawel Dokurno,Chen I-Jen,Natalia Matassova,Julia Smith,C. Pedder,Chris Graham,Aurélie Studeny,Gaëlle Lysiak-Auvity,Anne-Marie Girard,Fabienne Gravé,David J. Segal,David J. Segal,Chris D. Riffkin,Chris D. Riffkin,Giovanna Pomilio,Laura C. A. Galbraith,Laura C. A. Galbraith,Brandon J. Aubrey,Brandon J. Aubrey,Brandon J. Aubrey,Margs S. Brennan,Margs S. Brennan,Marco J Herold,Marco J Herold,Catherine Chang,Catherine Chang,Ghislaine Guasconi,Nicolas Cauquil,Fabien Melchiore,Nolwen Guigal-Stephan,Brian Lockhart,Frédéric Colland,John A. Hickman,Andrew W. Roberts,David C.S. Huang,David C.S. Huang,Andrew H. Wei,Andrew H. Wei,Andreas Strasser,Andreas Strasser,Guillaume Lessene,Guillaume Lessene,Olivier Geneste +66 more
TL;DR: It is demonstrated that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway.
Journal ArticleDOI
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?
Brandon J. Aubrey,Gemma L. Kelly,Gemma L. Kelly,Ana Janic,Ana Janic,Marco J Herold,Marco J Herold,Andreas Strasser,Andreas Strasser +8 more
TL;DR: Current understanding of the mechanisms by which p53 induces cell death is discussed and how this affects p53-mediated tumour suppression and the response of malignant cells to anticancer therapy is discussed.
Journal ArticleDOI
An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo
Brandon J. Aubrey,Gemma L. Kelly,Andrew J. Kueh,Andrew J. Kueh,Margs S. Brennan,Margs S. Brennan,Liam O’Connor,Liam O’Connor,Liz Milla,Liz Milla,Stephen Wilcox,Stephen Wilcox,Lin Tai,Andreas Strasser,Andreas Strasser,Marco J Herold,Marco J Herold +16 more
TL;DR: A drug-inducible small guide RNA (sgRNA) vector system allowing for ubiquitous and efficient gene deletion in murine and human cells mediates the efficient, temporally controlled deletion of MCL-1 in human Burkitt lymphoma cell lines that require this anti-apoptotic BCL-2 protein for sustained survival and growth.
Journal ArticleDOI
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Delphine Merino,Gemma L. Kelly,Guillaume Lessene,Andrew H. Wei,Andrew W. Roberts,Andreas Strasser,Andreas Strasser +6 more
TL;DR: The BCL-2 inhibitor venetoclax has been approved for treatment of refractory chronic lymphocytic leukemia and this drug and inhibitors of pro-survival MCL-1 and B CL-XL are being tested in diverse malignancies.
Journal ArticleDOI
Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2
TL;DR: A subset of BL tumors in which the Latency III-associated EBNA promoter Wp is active and most EBNAs are expressed, but where a gene deletion has specifically abrogated the expression of EBNA2 is identified, implying that BL can be selected from a Latencies III progenitor and that the principal selection pressure is for downregulation of the c-Myc antagonist EBNA 2.